AstraZeneca announced this week that it has agreed to the terms of a licensing agreement with China Medical System Holdings Ltd. (CMS) that will give CMS commercialization rights for Plendil (felodipine) in China. Read More »

Endocare Inc. has announced it has signed an exclusive agreement with R-Action Distribution Sarl, which is a subsidiary of R-Action SAS, that will allow the distribution of its Endocare Cryoablation technology in France and Switzerland. Read More »

AstraZeneca has announced it has completed an agreement that will transfer the rights of Moventig (naloxegol) to Kyowa Hakko Kirin subsidiary, ProStrakan Group. Read More »

Prime Therapeutics LLC, a company that manages pharmacy benefits and serves more than 26 million people, recently named Jonathan B. Gavras, M.D., as its new chief medical officer (CMO). Read More »

Earlier this week, the National Association of Chain Drug Stores (NACDS) issued a letter to members of the U.S. Senate to try and convince them to pass a legislation that would push for health care and enforcement authorities to work together for a solution to the prescription drug abuse problem in order to uphold patients’ legitimate access to medicines. Read More »

Astellas Pharma Inc. announced earlier this week that is has obtained approval from the Ministry of Health, Labour and Welfare in Japan for a supplemental new drug application (sNDA) for its product Kiklin capsules 250mg. Read More »

The American Pharmacists Association (APhA) announced this week that it has unveiled a new resource center in its continuing fight against prescription drug and opioid abuse that will provide pharmacists with more information pertaining to opioid use, abuse and misuse. Read More »

The American Pharmacists Association (APhA), in its efforts to uphold high standards of practicing nuclear pharmacy, has announced a series of educational sessions that will focus on nuclear pharmacy at its 2016 APhA Annual Meeting and Exposition Read More »

Actinium Pharmaceuticals announced this week that its choice for Clinical Research Organization (CRO) that will conduct its Phase 3 Iomab-B clinical trial is Medpace. Read More »

BioPlus Specialty Pharmacy has released a new version of its HCV Treatment Path app. Read More »

According to new data, researchers have found that stroke patients who have received medication via mail-service from pharmacies that offer the perk are more likely to follow their regimens and the guidelines of the medication. Read More »

Amgen announced earlier this week that it has submitted to the U.S. Food and Drug Administration (FDA) a supplemental Biologics License Application (sBLA) for BLINCYTO (blinatumomab) that will include new information to support the treatment of pediatric and adolescent patients who have been diagnosed with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Read More »

Astellas Pharma Inc. this week announced personnel changes for the company. Read More »

The American Society of Health-System Pharmacists (ASHP) has published a guide called "The Pharmacist’s Guide to Antimicrobial Therapy and Stewardship" to assist health care providers in fighting antimicrobial resistance to guarantee that patients are given the best treatments. Read More »

Altan Pharma Ltd. announced this week the signing of a licensure agreement that will commercialize a generic version of caspofungin. Read More »

Cipher Pharmaceuticals Inc. has appointed Ralph Bohrer as the president and general manager of its subsidiary located in the United States. Read More »

The top 15 pharmacies of 2015, ranked by total U.S. prescription dispensing revenues, are largely central-fill, mail and specialty pharmacies, according to a recent article released by the Drug Channels Institute. Read More »

Allergan recently announced the launch of its innovative new program, LILETTA + LILETTA Patient Commitment Program, which will allow patients who are eligible the opportunity to acquire a second LILETTA at no cost to them. Read More »

Sanofi US and Regeneron Pharmaceuticals Inc. announced last week that the two companies will receive exclusive or preferred access to Praluent (alirocumab) injections from Humana for commercial and Medicare patients. Read More »

Aimmune Therapeutics Inc. recently revealed data from the open-label ARC002 Phase 2 trial for its product, AR101, designed to treat peanut allergies. Read More »